Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 940 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Localized Cancer Clear all
Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

NCT06205836
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cemiplimab, Fianlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated Not applicable Interventional

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

NCT00469963
View directory record Official record
Conditions
Liver Cancer
Interventions
quality-of-life assessment, yttrium Y 90 resin microspheres
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Early Phase 1 Interventional

HCQ in Resectable Localized Prostate Cancer

NCT06408298
View directory record Official record
Conditions
Resectable Localized Prostate Cancer
Interventions
Hydroxychloroquine Sulfate 400Mg Tab, Placebo
Drug
Lead sponsor
Lionel.D.Lewis, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2Phase 3 Interventional

Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer

NCT01825642
View directory record Official record
Conditions
Prostate Cancer
Interventions
nerve-sparing radical prostatectomy, seminal vesicle-sparing radical prostatectomy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional

Evaluating Symptom Management Educational Materials for Patients With Prostate Cancer

NCT00769431
View directory record Official record
Conditions
Prostate Cancer
Interventions
educational intervention, study of socioeconomic and demographic variables
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 23, 2026, 5:19 PM EDT
Not listed Not applicable Interventional

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

NCT01972867
View directory record Official record
Conditions
Prostate Cancer
Interventions
NanoKnife Procedure
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated Phase 1 Interventional

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

NCT04185311
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Erdafitinib Intravesical Delivery System
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

NCT04530552
View directory record Official record
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer of The Liver

NCT00003147
View directory record Official record
Conditions
Liver Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
The Bronx, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

NCT03171025
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Not yet recruiting Phase 1 Interventional

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

NCT07385846
View directory record Official record
Conditions
Glioblastoma, Mismatch Repair Deficiency
Interventions
Pembrolizumab, Navifus Focused Ultrasound Sonification
Drug · Device
Lead sponsor
Jennifer Leddon
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

NCT06941324
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Best Practice, Communication Intervention, Discussion, Health Promotion and Education, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01426373
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
18
States / cities
Beverly Hills, California • La Jolla, California • San Juan Capistrano, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma

NCT00054002
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
adjuvant therapy, conventional surgery, porfimer sodium
Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

NCT00047333
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 23, 2026, 5:19 PM EDT
Active, not recruiting No phase listed Observational

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

NCT01608152
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Focus Group, Internet-Based Intervention, Interview
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Withdrawn Not applicable Interventional

Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma

NCT03168152
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Microwave Ablation (MWA), Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Feasibility of Transcranial Focused Ultrasound to Measure Brain Tumor

NCT05755399
View directory record Official record
Conditions
Cranial Neurosurgery
Interventions
Brain imaging using transcranial focused ultrasound (tFUS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses

NCT02248389
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sonatherm 600i ablation system
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

NCT04708067
View directory record Official record
Conditions
Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Bintrafusp Alfa, Biopsy, Hypofractionated Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed No phase listed Observational

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

NCT00806650
View directory record Official record
Conditions
Kidney Cancer
Interventions
gene expression analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method
Genetic · Diagnostic Test · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 23, 2026, 5:19 PM EDT
Completed No phase listed Observational

Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma

NCT01358617
View directory record Official record
Conditions
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Stage 4S Neuroblastoma
Interventions
diagnostic laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 23, 2026, 5:19 PM EDT